Qualigen therapeutics chief executive officer michael poirier provides letter to stockholders

Carlsbad, calif., feb. 01, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today issued the following letter to its stockholders:
QLGN Ratings Summary
QLGN Quant Ranking